Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
NCT ID: NCT00005012
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
250 participants
INTERVENTIONAL
2000-03-31
2000-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peginterferon alfa-2b
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have HIV levels of more than 2000 copies/ml.
* Have failed their current HAART (had a significant increase in their HIV levels with HAART).
* Have a CD4 cell count greater than 200 cells/microL.
* Have had more than 6 months of HAART.
* Have been on their current HAART for at least 6 weeks.
* Agree to use an effective method of birth control during the study.
Exclusion Criteria
* Have a history of a serious mental disorder.
* Are allergic to interferons.
* Are pregnant or breast-feeding.
* Are taking certain medications such as ribavirin, hydroxyurea, and ganciclovir.
0 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Schering-Plough
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Bay AIDS Ctr
Berkeley, California, United States
Georgetown Univ Med Ctr
Washington D.C., District of Columbia, United States
Dupont Circle Physicians Group
Washington D.C., District of Columbia, United States
IDC Research Initiative
Altamonte Springs, Florida, United States
Duval County Health Department
Jacksonville, Florida, United States
Univ of Miami School of Medicine
Miami, Florida, United States
Infectious Diseases Associates
Sarasota, Florida, United States
Piedmont Physicians at Vinings
Atlanta, Georgia, United States
TRIAD Health Practice
Chicago, Illinois, United States
Univ of Maryland Institute of Human Virology
Baltimore, Maryland, United States
New England Med Ctr / Div of Geo Med & Infect Disease
Boston, Massachusetts, United States
Regions Hosp
Saint Paul, Minnesota, United States
Washington Univ
St Louis, Missouri, United States
Southwestern New Jersey AIDS Clinical Trials
Camden, New Jersey, United States
East Orange Veterans Administration Med Ctr
East Orange, New Jersey, United States
Beth Israel Med Ctr
New York, New York, United States
Univ Hosps of Cleveland
Cleveland, Ohio, United States
MCP Hahnemann Univ
Philadelphia, Pennsylvania, United States
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States
Amelia Ct Clinic
Dallas, Texas, United States
Joseph C Gathe
Houston, Texas, United States
San Juan VAMC
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P00737
Identifier Type: -
Identifier Source: secondary_id
B010
Identifier Type: -
Identifier Source: org_study_id